{"id":"herceptin-trastuzuamb","safety":{"commonSideEffects":[{"rate":"5-27%","effect":"Cardiotoxicity / left ventricular dysfunction"},{"rate":"20-40%","effect":"Infusion reactions"},{"rate":"20-30%","effect":"Nausea"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-15%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trastuzumab targets human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain cancers. By binding to HER2, it prevents ligand-induced signaling and recruits immune cells to destroy HER2-positive cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).","oneSentence":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:06.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer"},{"name":"HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)"},{"name":"HER2-positive metastatic gastric cancer"}]},"trialDetails":[{"nctId":"NCT02514681","phase":"PHASE3","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2015-08-01","conditions":"HER2-positive Locally Advanced or Metastatic Breast Cancer","enrollment":226},{"nctId":"NCT04296942","phase":"PHASE1","title":"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-04","conditions":"Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer","enrollment":1},{"nctId":"NCT02149524","phase":"PHASE3","title":"A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-04","conditions":"HER2 Positive Early or Locally Advanced Breast Cancer","enrollment":875}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Herceptin"],"phase":"phase_3","status":"active","brandName":"Herceptin (trastuzuamb)","genericName":"Herceptin (trastuzuamb)","companyName":"Samsung Bioepis Co., Ltd.","companyId":"samsung-bioepis-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. Used for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings), HER2-positive metastatic gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}